Meet SoCal's Epic Sciences, One Of The Coolest Kids In Biopharma Right Now
Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.
Announced Thursday, the Series D was led by Hermed Capital with back-up from a diverse syndicate of investors, including Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital, and VI Ventures. Epic has now raised $85.5 million in equity financing since it spun out of the Scripps Research Institute in mid-2008.
Announced Thursday, the Series D was led by Hermed Capital with back-up from a diverse syndicate of investors, including Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital, and VI Ventures. Epic has now raised $85.5 million in equity financing since it spun out of the Scripps Research Institute in mid-2008.